These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 2491952

  • 1. A phase I study of thiotepa administered by short-term and protracted continuous intravenous infusion.
    Lokich JJ, Egorin MJ, Cohen BE, Bern MM, Zipoli TE, Moore C.
    Cancer; 1989 Jan 01; 63(1):46-50. PubMed ID: 2491952
    [Abstract] [Full Text] [Related]

  • 2. Phase I evaluation of thio-TEPA in combination with cisplatin for advanced gynecologic malignancies.
    Sandles LG, Freedman RS, Raber MN, Kavanagh J, Edwards CL, Scott WR, Wharton JT.
    Gynecol Oncol; 1990 Nov 01; 39(2):139-45. PubMed ID: 2121628
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Mitomycin C: phase I study of a constant infusion ambulatory treatment schedule.
    Lokich J, Perri J, Fine N, Bothe A, Nelson T, Greene R, Zipoli T.
    Am J Clin Oncol; 1982 Aug 01; 5(4):443-7. PubMed ID: 7113965
    [Abstract] [Full Text] [Related]

  • 7. [Treatment of disseminated breast cancer with triethylen-thiophosphoramide (thio-tepa)].
    Madrigal Alonso PL, Perez Gomez FJ.
    Acta Oncol (Madr); 1969 Aug 01; 8(2):135-42. PubMed ID: 4988905
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor.
    O'Dwyer PJ, LaCreta FP, Schilder R, Nash S, McAleer C, Miller LL, Hudes GR, Ozols RF.
    J Clin Oncol; 1992 Aug 01; 10(8):1352-8. PubMed ID: 1634926
    [Abstract] [Full Text] [Related]

  • 10. Continuous infusion carboplatin on a 21-day schedule: a phase I and pharmacokinetic study.
    Smit EF, Willemse PH, Sleijfer DT, Uges DR, Postmus PE, Meijer S, Terheggen PM, Mulder NH, de Vries EG.
    J Clin Oncol; 1991 Jan 01; 9(1):100-10. PubMed ID: 1985158
    [Abstract] [Full Text] [Related]

  • 11. A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies.
    Villalona-Calero MA, Petit T, Kuhn J, Cobb P, Kraynak M, Eckhardt SG, Drengler R, Simmons C, Santabarbara P, Von Hoff DD, Rowinsky EK.
    Clin Cancer Res; 1999 Nov 01; 5(11):3369-78. PubMed ID: 10589747
    [Abstract] [Full Text] [Related]

  • 12. Phase I trial of recombinant human macrophage colony-stimulating factor administered by continuous intravenous infusion in patients with metastatic cancer.
    Cole DJ, Sanda MG, Yang JC, Schwartzentruber DJ, Weber J, Ettinghausen SE, Pockaj BA, Kim HI, Levin RD, Pogrebniak HW.
    J Natl Cancer Inst; 1994 Jan 05; 86(1):39-45. PubMed ID: 8271281
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A phase I pharmacokinetic study of 21-day continuous infusion mitoxantrone.
    Greidanus J, de Vries EG, Mulder NH, Sleijfer DT, Uges DR, Oosterhuis B, Willemse PH.
    J Clin Oncol; 1989 Jun 05; 7(6):790-7. PubMed ID: 2715807
    [Abstract] [Full Text] [Related]

  • 15. Dosing of thioTEPA for myeloablative therapy.
    Przepiorka D, Madden T, Ippoliti C, Estrov Z, Dimopoulos M.
    Cancer Chemother Pharmacol; 1995 Jun 05; 37(1-2):155-60. PubMed ID: 7497586
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
    Zimmerman TM, Grinblatt DL, Malloy R, Williams SF.
    Cancer; 1998 Oct 15; 83(8):1540-5. PubMed ID: 9781947
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Prediction of hematologic toxicity of carboplatin by creatinine clearance rate.
    Taguchi J, Saijo N, Miura K, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Sakurai M, Minato K, Fujiwara Y.
    Jpn J Cancer Res; 1987 Sep 15; 78(9):977-82. PubMed ID: 3117753
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.